To clarify the possible involvement of uninhibited angiotensin II (Ang II) type 2 (AT 2 ) receptor stimulation in the effects of an Ang II type 1 (AT 1 ) receptor blocker, valsartan, we examined the cardiovascular remodeling induced by aortic banding with the use of wild-type (Agtr2ϩ) and AT 2 receptor null (Agtr2Ϫ) mice. Aortic banding caused cardiac hypertrophy in Agtr2ϩ and Agtr2Ϫ mice to a similar degree 6 weeks after surgery, whereas coronary arterial thickening and perivascular fibrosis were more exaggerated in Agtr2Ϫ mice. The AT 2 receptor was observed predominantly in the coronary arteries and perivascular region of Agtr2ϩ mice. Valsartan at a dose of 1 mg/kg per day, which did not influence systolic blood pressure, suppressed cardiac hypertrophy similarly in both strains. Valsartan inhibited coronary arterial thickening and perivascular fibrosis in both groups; however, the inhibitory effects of valsartan were significantly weaker in Agtr2Ϫ mice. The inhibitory effects of a nonselective Ang II receptor antagonist, [Sar 1 ,Ile 8 ]-Ang II, on cardiac hypertrophy, coronary artery thickening, and perivascular fibrosis were not significantly different in Agtr2ϩ and Agtr2Ϫ mice. These results suggest that the improvement by valsartan of coronary arterial thickening and perivascular fibrosis after pressure overload is caused by uninhibited AT 2 receptor stimulation in addition to AT 1 receptor blockade. (Arterioscler Thromb Vasc Biol. 2002;22:49-54.)
C ardiac hypertrophy is an adaptive response to hemodynamic or nonhemodynamic stimuli, such as hypertension and myocardial infarction, and is a major risk factor for heart failure. Accumulating evidence suggests that angiotensin II (Ang II) plays a critical role in the development of cardiac hypertrophy and cardiac remodeling. In addition to the classic Ang II type 1 (AT 1 ) receptor, another distinct receptor subtype of Ang II has been defined on the basis of differential pharmacological and biochemical properties and has been designated the Ang II type 2 (AT 2 ) receptor. 1 Recent evidence suggests that AT 2 receptors may exert antagonistic effects against the AT 1 receptor and that the balance of AT 1 and AT 2 receptors may determine cardiovascular remodeling. [2] [3] [4] [5] However, the functions of the recently cloned AT 2 receptor are still an enigma. In vitro studies have demonstrated that AT 2 receptor stimulation inhibits the growth of various cell types, including vascular smooth muscle cells (VSMCs), 6, 7 endothelial cells, 8 cardiomyocytes, 9, 10 and cardiac fibroblasts, 10 by counteracting the AT 1 receptor signaling. These findings have led us to hypothesize that the AT 2 receptor could exert antigrowth effects on cardiovascular remodeling. To examine the in vivo role of the AT 2 receptor in cardiac hypertrophy and cardiovascular remodeling, we developed a pressure overload-induced cardiac hypertrophy model in wild-type (Agtr2ϩ) and AT 2 receptor null (Agtr2Ϫ) mice. Arterial pressure and cardiomyocyte hypertrophy were similarly increased in the 2 strains after abdominal aortic banding. 11 In contrast, coronary arterial thickening and perivascular fibrosis were 50% greater in Agtr2Ϫ mice than in Agtr2ϩ mice. These results suggest that the AT 2 receptor exerts an inhibitory effect on coronary arterial remodeling.
The recent increase in the clinical application of AT 1 receptor blockers for the treatment of hypertension and heart failure has raised the question of the role of the simultaneous stimulation of the AT 2 receptor and the use of AT 1 receptor blockade in cardiovascular remodeling. Thus, to test this hypothesis in the present study, we used a pressure overloadinduced model of cardiac hypertrophy in the Agtr2Ϫ mouse, which provided us with a unique opportunity to address the pathophysiological role of AT 2 receptor combination with an AT 1 receptor blockade. which the temperature was kept at 25°C. They were given a standard diet (MF, Oriental Yeast Co Ltd) and water ad libitum. The Animal Studies Committee of Ehime University approved the experimental protocol.
Surgical Procedures
The surgical procedure of abdominal aortic banding was performed according to the method described previously. 11, 13 Briefly, the mice were anesthetized with ketamine (70 mg/kg) and xylazine (4 mg/kg) by intraperitoneal injection. The abdominal aorta was constricted at the suprarenal level with 7-0 nylon sutures with the use of a blunted 30-gauge needle, which was then pulled out. Sham operation was performed by isolation of the aorta without ligation. After the experimental period, the mice were killed by an overdose of anesthesia and perfused with PBS via an arterial catheter. Subsequently, the heart was perfusion-fixed at 100 mm Hg with 10% neutral buffered formalin. The hearts were excised, weighed, and postfixed in 10% neutral buffered formalin for histological analysis. Some Agtr2ϩ and Agtr2Ϫ mice were treated with valsartan, an AT 1 receptor blocker, or [Sar 1 ,Ile 8 ]-Ang II, a nonselective Ang II receptor blocker, by use of an osmotic minipump (model 1002, Alza) implanted intraperitoneally at the time of surgery. The pump delivered valsartan (1 mg/kg per day, provided by Novartis Pharma AG) or [Sar 1 ,Ile 8 ]-Ang II (1000 ng/kg per minute) continuously for 6 weeks at a rate of Ϸ0.25 L/h.
Morphometric Analysis
Fixed hearts were dehydrated and embedded in paraffin. The middle segment of the heart was cut into 5 subserial cross sections with a thickness of 5 m at intervals of 0.3 mm. The sections were stained with elastic van Gieson's stain for measurement of coronary arterial thickness, perivascular fibrosis area, and myocyte cross-sectional area. Regions in the left ventricular free wall were used for analysis. Suitable cross sections for measurement of cross-sectional area were defined as having nearly circular capillary profiles and nuclei, as previously reported. 11 To evaluate coronary arterial thickening and perivascular fibrosis, circular arteries with a long-axis-to-short-axis ratio Ͻ1.3 were chosen as suitable cross sections. The wall-toluminal area ratio, an index of arterial thickening, was defined as the ratio of cross-sectional medial area to luminal area. Perivascular fibrosis was assessed by calculating the ratio of the area of collagenstained material to total vessel area, which was defined as medial area plus luminal area. Each field was analyzed with imageanalyzing software (NIH Image). The average of Ͼ20 regions for myocytes and Ͼ10 regions for coronary arteries was taken as the value for each animal.
Immunohistochemistry
Frozen sections (5 m thick) were immunohistochemically stained by the streptavidin-biotin-peroxidase method, as described previously. 14 Briefly, endogenous peroxidase and the nonspecific binding of the antibody were blocked with 0.3% hydrogen peroxide in methanol and 2% goat serum in PBS, respectively. The antibody to ␣-smooth muscle actin (clone 1A4, Sigma Chemical Co), platelet and endothelial cell adhesion molecule-1 (PECAM-1, an antibody to endothelial cells; clone MEC 13.3, BD Biosciences), proliferating cell nuclear antigen (PCNA) antibody (clone PC10, Novocastra Laboratories Ltd), or normal rabbit serum diluted in 1% BSA in PBS was applied to the sections and incubated for 16 to 24 hours at 4°C. Subsequently, biotinylated secondary antibody and then streptavidin conjugate were applied. Positive staining was visualized with diaminobenzidine, and counterstaining with hematoxylin was performed.
Data Analysis
Values are expressed as meanϮSEM in the text and figures. Data were analyzed by 2-way ANOVA. If a statistically significant effect was found, the Newman-Keuls test was performed to detect the difference between the groups. A value of PϽ0.05 was considered to be statistically significant.
Results

Effects of AT 1 Receptor Blockade on Cardiac Hypertrophy Induced by Aortic Banding
As we previously reported, 11 suprarenal aortic banding for 6 weeks produced a systolic pressure gradient of nearly 40 mm Hg between the carotid and femoral arteries. No significant difference was found in mean arterial pressure in the carotid artery after aortic banding between Agtr2ϩ and Agtr2Ϫ mice. The degree of cardiomyocyte hypertrophy was evaluated by calculating the heart weight-to-body weight ratio (HW/BW ratio) and by measurement of the crosssectional area of cardiomyocytes. Consistent with previous results, 11 these parameters did not differ between Agtr2ϩ and Agtr2Ϫ mice in the sham-operated group (Figures 1 and 2 ). The HW/BW ratio and cross-sectional area of cardiomyo- cytes were increased to the same extent in Agtr2Ϫ mice and Agtr2ϩ mice 6 weeks after aortic banding. Continuous administration of an AT 1 receptor blocker, valsartan, at 1 mg/kg per day, which did not affect systolic blood pressure (data not shown), inhibited the increase in the HW/BW ratio significantly in both strains (PϽ0.05; Figure 1 , Table) .
Valsartan also significantly suppressed the increase in crosssectional area of cardiomyocytes to the basal level in both groups (PϽ0.05, Figure 2 ). Administration of [Sar 1 ,Ile 8 ]-Ang II, a nonselective Ang II blocker, also inhibited the pressure overload-induced increase in the HW/BW ratio and crosssectional area of cardiomyocytes similarly in Agtr2ϩ and Agtr2Ϫ mice ( Figures 1 and 2 , Table) .
Effects of AT 1 Receptor Blockade on Coronary Arterial Thickening and Perivascular Fibrosis After Aortic Banding
After aortic banding, coronary arterial thickening and perivascular fibrosis were observed. As shown in Figure 3 , these changes were exaggerated in Agtr2Ϫ mice. To analyze the histological changes quantitatively, we measured the medial area of the coronary arteries and fibrosis and then calculated each index in large (100ՅdiameterϽ200 m) and small (50ՅdiameterϽ100 m) coronary arteries separately, because the index-diameter relationship differed between large and small arteries. As shown in Figure 4 , top, the wall area-to-luminal area ratio, an index of coronary arterial thickening, in the left ventricle was 1.6-fold greater in Agtr2Ϫ mice than in Agtr2ϩ mice 6 weeks after aortic banding. We examined the cell populations in the thickened coronary arteries and observed that the major cell type was the VSMC (Figure 5A through 5F) and that the number of PCNA-positive cells was higher in Agtr2Ϫ mice than in Agtr2ϩ mice ( Figure 5G ). These results suggest that enhanced proliferation of VSMCs contributed to the exaggerated coronary artery thickening in Agtr2Ϫ mice after aortic banding. Treatment of mice with valsartan decreased coronary arterial thickening in Agtr2Ϫ as well as Agtr2ϩ mice, in large and small coronary arteries. However, this inhibitory action of valsartan was 1.7-fold weaker in the coronary arteries of Agtr2Ϫ mice than in those of Agtr2ϩ mice ( Figure  4 , top; Table) . The ratio of the collagen area to the total vessel area, an index of perivascular fibrosis, in the left ventricle was also higher in Agtr2Ϫ mice than in Agtr2ϩ mice 6 weeks after banding. Valsartan significantly reduced perivascular fibrosis in Agtr2ϩ and Agtr2Ϫ mice (PϽ0.05; Figure 4 , bottom; Table) . However, in the large as well as small coronary arteries, this inhibition was weaker in Agtr2Ϫ mice than in Agtr2ϩ mice (Figure 4 , bottom; Table) . In contrast, the inhibitory effects of [Sar 1 ,Ile 8 ]-Ang II on coronary artery thickening and perivascular fibrosis were similar in both strains of mice (Figure 4 , Table) .
Effects of Valsartan and [Sar 1 ,Ile 8 ]-Ang II on HW/BW Ratio, Cross-Sectional Area, Coronary Artery Thickening, and Perivascular Fibrosis Area
Discussion
Consistent with our previous results, 11 we confirmed that pressure overload induced morphological changes of cardiomyocyte hypertrophy, coronary arterial thickening, and perivascular fibrosis in mice. Of interest, coronary arterial thickening and perivascular fibrosis were exaggerated in Agtr2Ϫ mice compared with Agtr2ϩ mice, whereas cardiomyocyte hypertrophy developed similarly in the 2 strains. Using in vivo transfer of the AT 2 receptor gene into the balloon-injured rat carotid artery 6 and cuff placement around the femoral artery in Agtr2ϩ and Agtr2Ϫ mice, we have also shown that the AT 2 receptor can inhibit VSMC growth in vivo. 14 In vitro cell culture studies also suggest that the AT 2 receptor exerts growth-inhibitory effects on various cells. [7] [8] [9] [10] In contrast, Senbonmatsu et al 15 recently observed that targeted deletion of the mouse AT 2 receptor prevented left ventricular hypertrophy (assessed by echocardiography) resulting from pressure overload, implying that the AT 2 receptor is a mediator of cardiac hypertrophy in response to increased blood pressure. Abdominal banding was also used in their study, and some difference in the severity of the increase in blood pressure was found in their study compared with the present study. They reported that compared with the features of Agtr2ϩ mice, the features of Agtr2Ϫ mice included (1) normal ventricular function and (2) thinner ventricular wall thickness, whereas we did not observe such apparent morphological differences between our Agtr2ϩ and Agtr2Ϫ mice. They also observed that left ventricular and interstitial collagen type I was markedly reduced in aorticbanded Agtr2Ϫ mice compared with aortic-banded Agtr2ϩ mice. Moreover, they reported that targeted deletion of the mouse AT 2 receptor abolished left ventricular hypertrophy and cardiac fibrosis in mice with Ang II-induced hypertension. 16 In contrast, AT 2 receptor expression in the myocardium was not detectable before aortic banding, and we could not observe an apparent increase in AT 2 receptors in the myocardium after aortic banding in our previous study, 11 suggesting that it is difficult to clarify the role of the AT 2 receptor in cardiac hypertrophy in this pressure-overload cardiac hypertrophy model. The difference in genetic back- ground of Agtr2Ϫ mice may contribute to these apparent contradictory results, inasmuch as the genetic background of our Agtr2Ϫ mice is FVB/N and the genetic background of their mouse strain is C57BL/6. However, this possibility seems to be less important. Masaki et al 17 have reported that cardiac-specific overexpression of the AT 2 receptor gene with the use of ␣-myosin heavy chain promoter in the C57BL/6J mouse strain results in decreased sensitivity to AT 1 receptormediated pressor and chronotropic actions, that no obvious morphological change was observed in the myocardium, and that there was no significant difference in cardiac development or the HW/BW ratio between wild-type and transgenic mice. Moreover, using the same mouse strain (C57BL/6J), Sugino et al 18 reported that administration of a pressor dose of Ang II increased the HW/BW ratio to a similar degree in wild-type and AT 2 receptor transgenic mice. Moreover, Bartunek et al 19 reported that in adult Ang II-stimulated hypertrophied rat hearts, inhibition of cardiac AT 2 receptors, which were upregulated in chronic left ventricular hypertrophy, amplified the immediate left ventricular growth response to Ang II. It has also been suggested that AT 2 receptor stimulation may increase collagen synthesis in adult VSMCs and mesangial cells supplemented with retroviral gene transfer of the AT 2 receptor but not in fibroblasts transfected with the AT 2 receptor. 20 Tsutsumi et al 21 demonstrated that AT 2 receptor expression is upregulated in failing human hearts, that fibroblasts present in the interstitial regions are the major cell type responsible for its expression, and that the AT 2 receptor present in fibroblasts exerts an inhibitory effect on Ang II-induced fibrosis associated with heart failure. These apparently conflicting results may provide evidence for heterogeneity of the effects of AT 2 receptor stimulation in different tissues, cells, and/or different experimental conditions. These issues and the roles of the AT 2 receptor in the human myocardium should be addressed in the near future, because this new class of AT 1 receptor blocker appears to possess cardiovascular protective effects, and most of the beneficial effects provided by AT 1 receptor blockers appear to be related to more complete blockade of the AT 1 receptor; furthermore, costimulation of the AT 2 receptor appears to play some role in the improvement of cardiovascular remodeling.
In the present study, we demonstrated that treatment with valsartan effectively attenuated cardiac hypertrophy in Agtr2ϩ and Agtr2Ϫ mice, suggesting that valsartan inhibits the growth-promoting effects of Ang II via the AT 1 receptor in cardiomyocytes. In contrast, the effects of valsartan on the inhibition of coronary artery thickening and perivascular fibrosis were weaker in Agtr2Ϫ mice. Consistent with these results, as we previously reported, 11 AT 1 receptor binding was not different between the strains or the treatments, whereas the AT 2 receptor was observed predominantly in the coronary arteries and perivascular regions in Agtr2ϩ mice. Moreover, we observed that AT 1 receptor expression assessed immunohistochemically was comparable in the coronary arteries and perivascular regions of Agtr2ϩ and Agtr2Ϫ mice (data not shown). We also observed that the inhibitory effects of a nonselective Ang II receptor antagonist, [Sar 1 ,Ile 8 ]-Ang II, on cardiac hypertrophy, coronary artery thickening, and perivascular fibrosis were not different between Agtr2ϩ and Agtr2Ϫ mice. Therefore, we can speculate that stimulation of the AT 2 receptor after the administration of an AT 1 receptor blocker is proportional to the degree of receptor blockade. Indeed, Liu et al, 22 using a model of heart failure induced by myocardial infarction in rats, demonstrated that an AT 1 receptor antagonist improved cardiac function and decreased interstitial collagen deposition and cardiomyocyte size and that these effects were blocked by the AT 2 antagonist, suggesting that part of the effect of the AT 1 receptor antagonist was due to stimulation of the AT 2 receptor. Siragy et al 23 also reported that AT 1 receptor blockade by valsartan was associated with stimulation of the AT 2 receptor, which mediates a renal bradykinin and NO cascade and decreases blood pressure. Our results clearly support the notion that AT 2 receptor stimulation along with the use of valsartan contributes to the effect of valsartan in the improvement of cardiac remodeling and that the AT 2 receptor plays important roles in cardiac remodeling, such as coronary artery thickening and fibrosis in pressure-overload cardiac hypertrophy.
Coronary arterial thickening as a result of VSMC hypertrophy or hyperplasia may lead to coronary narrowing and decreased coronary reserve, and cardiac fibrosis may lead to decreased compliance and increased myocardial stiffness, suggesting the pathophysiological and clinical importance of the AT 2 receptor in cardiac hypertrophy. The specific blockade of the AT 1 receptor by valsartan not only may abrogate AT 1 receptor signaling but also may increase Ang II binding to uninhibited AT 2 receptors, leading to the inhibition of coronary arterial remodeling, such as medial hypertrophy and perivascular fibrosis, resulting in the improvement of cardiovascular remodeling.
